Highlights

  • Six analysts currently maintain a Moderate Buy consensus on SABS shares.
  • Recent coverage updates reflect varied ratings and revised target prices.
  • Institutional investors reported new positions and portfolio adjustments during the third quarter.

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) are currently followed by six research firms, with analyst coverage resulting in an average rating described as Moderate Buy. According to available analyst data, one firm has issued a Sell rating, four analysts have assigned Buy ratings, and one has issued a Strong Buy rating. The average twelve-month target price across analysts that updated coverage over the past year stands at USD 10.75.

Several brokerage firms have published research updates on SAB Biotherapeutics in recent months. Wall Street Zen revised its rating on the stock from Sell to Hold in a report issued in late November. Chardan Capital reaffirmed a Buy rating in December and set a price objective of USD 12.00. Leerink Partners initiated coverage earlier in the year, assigning an Outperform rating along with a USD 7.00 price target. Guggenheim also began coverage in December, issuing a Buy rating and establishing a USD 15.00 target price. In contrast, Weiss Ratings reiterated a Sell (D) rating in a late-December research note.

Institutional investment activity in SAB Biotherapeutics reflected both inflows and new position initiations during the third quarter. Woodline Partners LP disclosed the purchase of a new stake valued at approximately USD 5.73 million. Vivo Capital LLC reported a new investment of about USD 22.95 million, while RA Capital Management L.P. and Commodore Capital LP each disclosed new positions valued near USD 8.85 million. Virtu Financial LLC also reported a smaller new position during the same period. Collectively, hedge funds and other institutional investors hold approximately 7.82% of the company’s outstanding shares.

SAB Biotherapeutics is a clinical-stage biotechnology company focused on the development of fully human polyclonal antibody therapies. Its proprietary Tc Bovine® platform utilizes genetically engineered cattle to produce human antibodies designed to target specific disease antigens. The company’s current development efforts are primarily directed toward treatments for infectious diseases, with programs in various stages of clinical evaluation.

Shares of SABS last traded at USD 3.78 on December 24, 2025.